Skip to content

    Recently Viewed

      Listening...

      Statement on the Release of the 2017 Janssen U.S. Transparency Report

      Statement on the release of the 2017 Janssen U.S. Transparency Report

      Share Article
      share to

      Titusville, NJ – (March 8, 2018) – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson issued their 2017 Janssen U.S. Transparency Report, available at Janssen.com/2017USTransparencyReport. Joaquin Duato, Executive Vice President and Worldwide Chairman of Pharmaceuticals for Johnson & Johnson, issued the following statement on the release of the report:

      “As our second annual Janssen U.S. Transparency Report shows, in 2017 the net price of our medicines in the U.S. decreased while we increased to $7.9 billion our investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases. Our report demonstrates our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines and help people who need Janssen medicines get access to them.

      “We issue this report because we believe open dialogue is essential to developing a more results-based healthcare system that delivers what we all want: greater access to care, at more manageable cost, and, most importantly, better health for all.”

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.